Montreal-based Perceiv AI is using precision medicine to increase the efficiency of drug development and testing.
Until recently, the development of medications and treatment regimes for patients relied on a one-size-fits-all approach. It took limited variables into account, adjusting primarily for weight, age, and progression of the illness. This process involved trial and error; patients and doctors could spend a significant amount of time trying different medications until finding the right one for the individual. This means potential pain and symptoms, frustration, and cost for the patient.
The traditional approach is equally problematic for drug development. Creating a treatment for a specific disease means the drug must work for the average person instead of the individual. This general approach leads to a higher chance of adverse effects, ineffective treatments, and a very long road from discovery and development to market.
The application of artificial intelligence in the healthcare industry has allowed for fast advancements across all different areas, from treatments of mental illness to more accurate diagnostics. In contrast to the one-size-fits-all approach, precision medicine can take thousands and even millions of individual variabilities into account. Everything that impacts how a patient will respond to treatment, such as their genetics, lifestyle, medical history, and much more, can be considered.
Perceiv AI is one of the startups using precision medicine to make treatments and drug development cheaper, more efficient, and to provide a better outcome for patients. Foresight, their precision medicine platform, builds a profile of an individual patient from several sources: bloodwork, imaging, genetics, clinical data, and molecular information. The exact characterisation of patients provides a way for clinical trials to find the most suitable study participants. In the case of patients requiring treatment, Perceiv AI offers outcome prediction to find the best treatment option without trial and error.
Their precision medicine platform is currently being used to better classify Alzheimer’s patients for clinical trials. Alzheimer’s is a complex and highly individual disease which is why 99.6% of Alzheimer’s trials can fail. Perceiv AI uses precision medicine to identify more subgroups of Alzheimer’s disease patients to find the best participants for each trial.